Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose Chemokines influence both tumor progression and anti-tumor immune response. A 32-bp-deletion polymorphism in the chemokine receptor 5 gene (CCR5Delta32) has been shown to result in a non-functional protein. This study was aimed at evaluating the potential impact of this gene polymorphism on disease progression and treatment outcome in patients with melanoma.Patients and methods CCR5 genotyping was performed by PCR on DNA extracted from serum samples of 782 cutaneous melanoma patients with known disease history and long-term clinical follow-up. Genotypes were correlated with patient survival and types of treatment.Results Of 782 melanoma patients, 90 (11.5%) were heterozygous and 12 (1.5%) were homozygous for CCR5Delta32. Analyzing the complete cohort, the disease-specific survival from date of primary diagnosis was not influenced by CCR5 status. Similarly, no significant impact could be detected on the treatment outcome of stage III patients. In 139 stage IV patients receiving immunotherapy, CCR5Delta32 was associated with a decreased survival compared to patients not carrying the deletion (median 12.5 vs. 20.3 months, P = 0.029). Multivariate analysis revealed the CCR5 genotype as an independent factor impacting disease-specific survival in this patient population (P = 0.002), followed by gender (P = 0.019) and pathological classification of the primary (pT; P = 0.022).Conclusion The presence of the CCR5Delta32 polymorphism in patients with stage IV melanoma results in a decreased survival following immunotherapy and may help to select patients less likely to benefit from this type of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline polymorphisms in immune regulatory genes also have the potential to influence the magnitude of spontaneous anti-tumor T cell responses (17).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [17]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636 · cited 2×
“The pathological classiWcation of the primary (pT) was used to combine the parameters depth of invasion and ulceration, the classiWcation of distant metastasis (M) was used to combine the parameters distant metastasis localization and serum LDH, both according to AJCC 2001 staging criteria [16].”
MethodInternational Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., & Power, C. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01439-x · Cited by 1,817 · cited 1×
“inXammatory protein (MIP)-1 and MIP-1 ), and CCL5 [regulated-upon-activation, T cell expressed and secreted (RANTES)] facilitate CCR5-expressing immunocompetent dendritic cells and CD4 T cells to migrate towards inXammatory stimuli [1, 2].”
BackgroundThe role of a mutant CCR5 allele in HIV–1 transmission and disease progression
Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1240 · Cited by 1,358 · cited 1×
“A 32 bp deletion in the CCR5 gene (CCR5 32) abolishes receptor expression in homozygous individuals and results in a decreased receptor expression in heterozygous carriers compared to wild-type homozygotes [11].”
BackgroundThe Efficiency of Cox's Likelihood Function for Censored Data
Efron, B. (1977) · Journal of the American Statistical Association · doi:10.1080/01621459.1977.10480613 · Cited by 1,228 · cited 1×
“The approximation of Efron [ 17 ] was used to treat ties correctly and P values were calculated using the Wald statistic.”
MethodThurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Self-citationMartingale-based residuals for survival models
THERNEAU, T. M., GRAMBSCH, P. M., & FLEMING, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.1.147 · Cited by 1,099 · cited 1×
“To examine the assumption of proportional hazards in a Cox regression model the scaled Schoenfeld residuals [ 18 ] and a chisquared test on each covariate were utilized.”
MethodChemokines and Cell Migration in Secondary Lymphoid Organs
Cyster, J. G. (1999) · Science · doi:10.1126/science.286.5447.2098 · Cited by 1,031 · cited 1×
“inXammatory protein (MIP)-1 and MIP-1 ), and CCL5 [regulated-upon-activation, T cell expressed and secreted (RANTES)] facilitate CCR5-expressing immunocompetent dendritic cells and CD4 T cells to migrate towards inXammatory stimuli [1, 2].”
BackgroundGlobal distribution of the CCR5 gene 32-basepair deletion
Martinson, J. J., Chapman, N. H., Rees, D. C., Liu, Y.-T., & Clegg, J. B. (1997) · Nature Genetics · doi:10.1038/ng0597-100 · Cited by 539 · cited 3×
“For example, in central Europe high frequencies (around 10%) of CCR5 32 are observed, whereas the deletion is virtually absent in African, Asian, Middle Eastern and American Indian populations [13].”
BackgroundResultInfluential
Cited by
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
“The naturally occurring CCR5∆32 polymorphism, which results in a non-functional CCR5 protein and reduced CCR5 surface expression in human heterozygotes, has been associated with poor efficacy of IFNα or interleukin-2 (IL2) immunotherapy in melanoma (Ugurel et al., 2008).”
BackgroundCytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
“A defined polymorphism in the CCR5 gene (CCR5Δ32) was associated with decreased survival following IL-2 administration in patients with Stage IV melanoma compared to patients not carrying the deletion [87].”
BackgroundDjenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402711 · Cited by 622
“tration, poor prognosis (48, 49), and reduced efficacy of cancer immunotherapy (50).”
Background
Metadata
- Authors
- Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C.
- Affiliations
- University of Würzburg (DE)
- German Cancer Research Center (DE)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Becker, Jürgen C.
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2007-10-02
- Volume
- 57
- Issue
- 5
- Pages
- 685-691
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11030845
- OpenAlex
- W2090347584
- Cited by
- 88
- References
- 24
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 9 · 2012: 9
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wilhelm Sander-Stiftung
- Topics
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CCR5, metastatic melanoma, immunotherapy, disease-specific survival, chemokine receptors, stage IV melanoma, treatment outcomes, patient selection, chemokines, antitumor immunity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Polymorphism, Genetic, Skin Neoplasms, Treatment Outcome, Receptors, CCR5, Reverse Transcriptase Polymerase Chain Reaction, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. https://app.cochat.ai/papers/10.1007/s00262-007-0407-z
- The paper
- Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008). Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-007-0407-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.